Key result
Acute PE risk stratification guides ambulatory care and prevents treatment delays affecting ~20% of patients.
Why the study?
Despite clinical guidelines emphasizing risk stratification in pulmonary embolism, a large proportion of patients lacked documented risk stratification, leading to unnecessary admissions or inappropriate outpatient management.
Modern management of acute pulmonary embolism requires formal risk stratification to appropriately triage patients to ambulatory care, observation, or urgent reperfusion.
Answers are grounded in this paper and cite their sources.
Most VTE deaths occur in high/intermediate-high risk PE despite advances; leaves open need for targeted research on novel high-risk therapies.
Introduction In the past few decades, significant developments in the prevention, diagnosis, and treatment of acute pulmonary embolism have emerged. Despite this, pulmonary embolism remains a major cause of morbidity and mortality, with an estimated 25 000 deaths from venous thromboembolism annually in England. The vast majority of these deaths occur in those with high or intermediate high-risk pulmonary embolism. Recent guidelines from the British Thoracic Society and European Society of Cardiology emphasize the necessity of clinical risk stratification. However, the 2019 National Confidential Enquiry into Patient Outcome and Death report, Know the Score, revealed that a large proportion of patients had no documented risk stratification, leading to both unnecessary admissions for low-risk patients and inappropriate outpatient management for those at higher risk. Risk stratification and ambulatory care A fundamental shift in management is the drive toward ambulatory (outpatient) care, often in same-day emergency clinics. Identifying suitable candidates requires validated scoring systems. Low risk Defined by a Pulmonary Embolism Severity Index (PESI) Class I/II, simplified PESI (sPESI) of 0, or Hestia score of 0. Intermediate low risk Categorized by the presence of right ventricular dysfunction (on CT pulmonary angiogram or echocardiography) or elevated cardiac biomarkers (troponin or N-terminal pro-B-type natriuretic peptide). Intermediate high risk Categorized by the presence of right ventricular dysfunction (on CT pulmonary angiogram or echocardiography) and elevated cardiac biomarkers (troponin or N-terminal pro-B-type natriuretic peptide). High risk Defined by haemodynamic instability (systolic blood pressure < 90 mmHg or a drop of >40 mmHg). Clinical application using case studies The spectrum of pulmonary embolism management is best illustrated through distinct clinical phenotypes. Management of low-risk patients Patients presenting with stable observations and low clinical risk scores (e.g. sPESI 0) are eligible for ambulatory care. The 2019 European Society of Cardiology guidelines support early discharge when robust outpatient anticoagulation pathways are in place. Direct oral anticoagulants are now preferred over traditional vitamin K antagonists or low molecular weight heparin bridging. Crucially, the National Confidential Enquiry into Patient Outcome and Death Report identified avoidable treatment delays in nearly a fifth of cases; clinicians should administer an interim anticoagulation dose if diagnostic imaging is delayed by more than 1 h. Management of intermediate-risk patients Intermediate-risk patients require admission for a period of observation. Those with intermediate-high risk (evidence of both right ventricular strain and positive biomarkers) carry a significant risk of early decompensation. Consequently, these patients should be monitored closely for the first 72 h, with “rescue” reperfusion considered for those who deteriorate or fail to adequately improve. This could be in the form of systemic thrombolysis or catheter-directed therapies, depending on patient risks, local expertise, guidance, and availability. Further risk assessment and monitoring could be considered using the Composite Pulmonary Embolism Shock (CPES) score (which includes elevated troponin, elevated B-type natriuretic peptide, reduced right ventricular function on imaging, markers of central thrombus, concomitant deep vein thrombosis and tachycardia), as well as tracking serum lactate concentration and the required fraction of inspired oxygen. Management of high-risk patients (massive pulmonary embolism) Patients with hemodynamic instability require consideration for urgent reperfusion. Unfractionated heparin is a useful initial anticoagulant due to its rapid onset and reversibility, but low molecular weight heparin is often used for ease of administration and reduced monitoring requirements. Systemic thrombolysis (e.g. alteplase) remains the standard of care. For patients where thrombolysis is contraindicated or has failed, surgical embolectomy or percutaneous catheter-directed treatment (e.g. ultrasound-facilitated fibrinolysis or thromboaspiration) should be considered. In refractory cases, extracorporeal membrane oxygenation may provide a viable bridge to recovery. Conclusions Modern pulmonary embolism management relies on moving beyond simple diagnosis to formal risk stratification. Utilizing PESI/sPESI scores and assessment of right ventricular function allows for the safe expansion of care via same day emergency care while identifying high-risk patients who require intensive monitoring or invasive reperfusion. Standardizing the documentation of these risk assessments is essential to improve patient outcomes, with pulmonary embolism response teams and local specialist networks providing multidisciplinary care, aiming to minimize the morbidity and mortality for this condition. References 1. Howard LS, Barden S, Condliffe R, et al. British Thoracic Society Guideline for the initial outpatient management of pulmonary embolism. BMJ Open Respir Res 2018;5(1). 2. Konstantinides SV, Meyer G, Becattini C, et al. 2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS). Eur Heart J 2020;41:543–603. 3. NCEPOD. “Know the Score”: A review of the quality of care provided to patients with a new diagnosis of pulmonary embolism. 2019. 4. Zhang RS, Yuriditsky E, Zhang P, et al.. Composite Pulmonary Embolism Shock Score and Risk of Adverse Outcomes in Patients with Pulmonary Embolism. Circ Cardiovasc Interv 2024;17:e014088.
No takes yet. Share an insight, caveat, or question.
Nick Murch (2026) conducted a review in Acute pulmonary embolism. Formal risk stratification in acute pulmonary embolism is essential to guide ambulatory care for low-risk patients and avoid treatment delays, which currently occur in nearly 20% of cases.
Synapse has enriched 10 related papers. Consider them for comparative context: